Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Massachusetts General Hospital · Harvard University · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,328
total citations
- FWCI
- 40.43
- Percentile
- 100%
- References
- 21
Citations per year
Authors
21- JAJeffrey A. Engelman
Massachusetts General Hospital, Harvard University, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Hospital, Center for Cancer Research
- LCLiang Chen
Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
- XTXiaohong Tan
Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
- KCKatherine Crosby
Cell Signaling Technology (United States)
- ARAlexander R. Guimarães
Athinoula A. Martinos Center for Biomedical Imaging, Center for Systems Biology, Harvard University, Massachusetts General Hospital
Topics & keywords
Topics
Keywords
- KRAS
- P110α
- PI3K/AKT/mTOR pathway
- Cancer research
- MEK inhibitor
- Mutant
- Lung cancer
- Kinase
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.